Cargando…

A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns

BACKGROUND: Active tuberculosis (TB) case finding is important as it helps detect pulmonary TB cases missed by the other active screening methods. It requires periodic mass screening in risk population groups such as prisoners and refugees. Unfortunately, in these risk population groups periodic mas...

Descripción completa

Detalles Bibliográficos
Autores principales: Donkeng-Donfack, Valerie Flore, Tchatchueng-Mbougua, Jules Brice, Abanda, Ngu Njei, Ongboulal, Suzanne Magloire, Djieugoue, Yvonne Josiane, Kamdem Simo, Yannick, Mekemnang Tchoupa, Micheline, Bekang Angui, Frédéric, Kuate Kuate, Albert, Mbassa, Vincent, Mvondo Abeng Belinga, Edwige, Eyangoh, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895851/
https://www.ncbi.nlm.nih.gov/pubmed/35246071
http://dx.doi.org/10.1186/s12879-022-07157-0
_version_ 1784663018637885440
author Donkeng-Donfack, Valerie Flore
Tchatchueng-Mbougua, Jules Brice
Abanda, Ngu Njei
Ongboulal, Suzanne Magloire
Djieugoue, Yvonne Josiane
Kamdem Simo, Yannick
Mekemnang Tchoupa, Micheline
Bekang Angui, Frédéric
Kuate Kuate, Albert
Mbassa, Vincent
Mvondo Abeng Belinga, Edwige
Eyangoh, Sara
author_facet Donkeng-Donfack, Valerie Flore
Tchatchueng-Mbougua, Jules Brice
Abanda, Ngu Njei
Ongboulal, Suzanne Magloire
Djieugoue, Yvonne Josiane
Kamdem Simo, Yannick
Mekemnang Tchoupa, Micheline
Bekang Angui, Frédéric
Kuate Kuate, Albert
Mbassa, Vincent
Mvondo Abeng Belinga, Edwige
Eyangoh, Sara
author_sort Donkeng-Donfack, Valerie Flore
collection PubMed
description BACKGROUND: Active tuberculosis (TB) case finding is important as it helps detect pulmonary TB cases missed by the other active screening methods. It requires periodic mass screening in risk population groups such as prisoners and refugees. Unfortunately, in these risk population groups periodic mass screening can be challenging due to lengthy turnaround time (TAT), cost and implementation constraints. The aim of this study was to evaluate a diagnostic algorithm that can reduce the TAT and cost for TB and Rifampicin resistance (RR) detection. The algorithm involves testing with TB-LAMP followed by Xpert MTB/RIF for positive TB-LAMP cases to diagnose TB during mass campaigns in prisons and refugee camps. METHODS: The National Tuberculosis Control Program (NTCP) organized routine TB mass-screening campaigns in 34 prisons and 3 villages with refugees camps in Cameroon in 2019. TB LAMP was used for initial TB diagnosis and all TB-LAMP positive cases tested with the Xpert MTB/RIF assay to determine RR. TAT and cost benefits analysis of the combined use of TB-LAMP and Xpert MTB/RIF assays was determined and compared to the Xpert MTB/RIF assay when used only. RESULTS: A total of 4075 sputum samples were collected from TB presumptive, 3672 cases in 34 prisons and 403 samples in 3 villages. Of the 4,075 samples screened with TB-LAMP, 135 were TB positive (3.31%) and run on the Xpert MTB/RIF. Of the 135 positives cases, Xpert MTB/RIF revealed 3 were RR (2.22%). The use of TB-LAMP followed by testing with Xpert MTB/RIF for TB and RR detection reduced the TAT by 73.23% in prisons and 74.92% in villages. In addition to a reduced TAT, the two molecular tests used in synergy is cost benefit from year 2 onwards. CONCLUSION: This study demonstrates the advantages of a diagnostic algorithm based on an initial testing with TB-LAMP followed by testing with Xpert MTB/RIF for TB diagnosis. This approach improved early and rapid TB detection with an added advantage of providing RR status. The proposed algorithm is effective and less costly from the second year of implementation and should be used by TB control programs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07157-0.
format Online
Article
Text
id pubmed-8895851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88958512022-03-10 A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns Donkeng-Donfack, Valerie Flore Tchatchueng-Mbougua, Jules Brice Abanda, Ngu Njei Ongboulal, Suzanne Magloire Djieugoue, Yvonne Josiane Kamdem Simo, Yannick Mekemnang Tchoupa, Micheline Bekang Angui, Frédéric Kuate Kuate, Albert Mbassa, Vincent Mvondo Abeng Belinga, Edwige Eyangoh, Sara BMC Infect Dis Technical Advance BACKGROUND: Active tuberculosis (TB) case finding is important as it helps detect pulmonary TB cases missed by the other active screening methods. It requires periodic mass screening in risk population groups such as prisoners and refugees. Unfortunately, in these risk population groups periodic mass screening can be challenging due to lengthy turnaround time (TAT), cost and implementation constraints. The aim of this study was to evaluate a diagnostic algorithm that can reduce the TAT and cost for TB and Rifampicin resistance (RR) detection. The algorithm involves testing with TB-LAMP followed by Xpert MTB/RIF for positive TB-LAMP cases to diagnose TB during mass campaigns in prisons and refugee camps. METHODS: The National Tuberculosis Control Program (NTCP) organized routine TB mass-screening campaigns in 34 prisons and 3 villages with refugees camps in Cameroon in 2019. TB LAMP was used for initial TB diagnosis and all TB-LAMP positive cases tested with the Xpert MTB/RIF assay to determine RR. TAT and cost benefits analysis of the combined use of TB-LAMP and Xpert MTB/RIF assays was determined and compared to the Xpert MTB/RIF assay when used only. RESULTS: A total of 4075 sputum samples were collected from TB presumptive, 3672 cases in 34 prisons and 403 samples in 3 villages. Of the 4,075 samples screened with TB-LAMP, 135 were TB positive (3.31%) and run on the Xpert MTB/RIF. Of the 135 positives cases, Xpert MTB/RIF revealed 3 were RR (2.22%). The use of TB-LAMP followed by testing with Xpert MTB/RIF for TB and RR detection reduced the TAT by 73.23% in prisons and 74.92% in villages. In addition to a reduced TAT, the two molecular tests used in synergy is cost benefit from year 2 onwards. CONCLUSION: This study demonstrates the advantages of a diagnostic algorithm based on an initial testing with TB-LAMP followed by testing with Xpert MTB/RIF for TB diagnosis. This approach improved early and rapid TB detection with an added advantage of providing RR status. The proposed algorithm is effective and less costly from the second year of implementation and should be used by TB control programs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07157-0. BioMed Central 2022-03-04 /pmc/articles/PMC8895851/ /pubmed/35246071 http://dx.doi.org/10.1186/s12879-022-07157-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Technical Advance
Donkeng-Donfack, Valerie Flore
Tchatchueng-Mbougua, Jules Brice
Abanda, Ngu Njei
Ongboulal, Suzanne Magloire
Djieugoue, Yvonne Josiane
Kamdem Simo, Yannick
Mekemnang Tchoupa, Micheline
Bekang Angui, Frédéric
Kuate Kuate, Albert
Mbassa, Vincent
Mvondo Abeng Belinga, Edwige
Eyangoh, Sara
A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
title A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
title_full A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
title_fullStr A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
title_full_unstemmed A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
title_short A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
title_sort cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895851/
https://www.ncbi.nlm.nih.gov/pubmed/35246071
http://dx.doi.org/10.1186/s12879-022-07157-0
work_keys_str_mv AT donkengdonfackvalerieflore acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT tchatchuengmbouguajulesbrice acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT abandangunjei acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT ongboulalsuzannemagloire acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT djieugoueyvonnejosiane acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT kamdemsimoyannick acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT mekemnangtchoupamicheline acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT bekanganguifrederic acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT kuatekuatealbert acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT mbassavincent acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT mvondoabengbelingaedwige acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT eyangohsara acostbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT donkengdonfackvalerieflore costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT tchatchuengmbouguajulesbrice costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT abandangunjei costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT ongboulalsuzannemagloire costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT djieugoueyvonnejosiane costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT kamdemsimoyannick costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT mekemnangtchoupamicheline costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT bekanganguifrederic costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT kuatekuatealbert costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT mbassavincent costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT mvondoabengbelingaedwige costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns
AT eyangohsara costbenefitalgorithmforrapiddiagnosisoftuberculosisandrifampicinresistancedetectionduringmassscreeningcampaigns